13,500 Shares in Arrowhead Pharmaceuticals, Inc. $ARWR Acquired by Moody Lynn & Lieberson LLC

Key Points

• Moody Lynn & Lieberson LLC acquired 13,500 shares of Arrowhead Pharmaceuticals, valued at approximately $213,000, during the second quarter.
• Several institutional investors, including Vanguard Group and Goldman Sachs, have recently increased their holdings in Arrowhead Pharmaceuticals, indicating strong institutional interest.
• Arrowhead Pharmaceuticals reported earnings of ($1.26) per share for the last quarter, missing analyst expectations, with a consensus rating of "Buy" and an average price target of $43.14.

Moody Lynn & Lieberson LLC acquired a new position in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 13,500 shares of the biotechnology company's stock, valued at approximately $213,000.

A number of other institutional investors have also recently added to or reduced their stakes in the business. Vanguard Group Inc. grew its holdings in Arrowhead Pharmaceuticals by 8.4% during the 1st quarter. Vanguard Group Inc. now owns 13,202,562 shares of the biotechnology company's stock worth $168,201,000 after acquiring an additional 1,018,273 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its holdings in Arrowhead Pharmaceuticals by 138.0% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 4,785,062 shares of the biotechnology company's stock worth $60,962,000 after acquiring an additional 2,774,933 shares during the last quarter. T. Rowe Price Investment Management Inc. grew its holdings in Arrowhead Pharmaceuticals by 0.9% during the 1st quarter. T. Rowe Price Investment Management Inc. now owns 2,528,982 shares of the biotechnology company's stock worth $32,220,000 after acquiring an additional 21,686 shares during the last quarter. Goldman Sachs Group Inc. grew its holdings in Arrowhead Pharmaceuticals by 34.6% during the 1st quarter. Goldman Sachs Group Inc. now owns 1,741,666 shares of the biotechnology company's stock worth $22,189,000 after acquiring an additional 447,456 shares during the last quarter. Finally, Aberdeen Group plc grew its holdings in Arrowhead Pharmaceuticals by 138.4% during the 1st quarter. Aberdeen Group plc now owns 1,072,827 shares of the biotechnology company's stock worth $13,668,000 after acquiring an additional 622,752 shares during the last quarter. 62.61% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on ARWR shares. TD Cowen raised shares of Arrowhead Pharmaceuticals to a "strong-buy" rating in a report on Monday, July 28th. Chardan Capital reissued a "buy" rating and set a $60.00 target price on shares of Arrowhead Pharmaceuticals in a report on Monday, August 11th. HC Wainwright reaffirmed a "buy" rating and issued a $80.00 price objective on shares of Arrowhead Pharmaceuticals in a research note on Tuesday, September 2nd. Royal Bank Of Canada reduced their price objective on shares of Arrowhead Pharmaceuticals from $40.00 to $38.00 and set an "outperform" rating on the stock in a research note on Friday, August 8th. Finally, B. Riley raised shares of Arrowhead Pharmaceuticals to a "strong-buy" rating in a research note on Monday, August 11th. Two equities research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating and two have given a Hold rating to the company's stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and an average price target of $43.14.

Insider Transactions at Arrowhead Pharmaceuticals

In related news, insider James C. Hamilton sold 15,000 shares of the stock in a transaction on Friday, September 12th. The shares were sold at an average price of $30.00, for a total transaction of $450,000.00. Following the transaction, the insider directly owned 232,122 shares of the company's stock, valued at $6,963,660. This represents a 6.07% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders have sold 40,000 shares of company stock worth $1,025,000 over the last 90 days. 4.30% of the stock is owned by corporate insiders.

Arrowhead Pharmaceuticals Stock Up 3.0%

Shares of NASDAQ ARWR opened at $33.78 on Tuesday. The firm has a market cap of $4.67 billion, a PE ratio of -26.39 and a beta of 1.00. Arrowhead Pharmaceuticals, Inc. has a 12-month low of $9.57 and a 12-month high of $34.16. The company's fifty day simple moving average is $22.99 and its 200 day simple moving average is $17.66. The company has a quick ratio of 4.87, a current ratio of 4.87 and a debt-to-equity ratio of 0.39.

Arrowhead Pharmaceuticals (NASDAQ:ARWR - Get Free Report) last issued its earnings results on Thursday, August 7th. The biotechnology company reported ($1.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.94) by ($0.32). The company had revenue of $27.77 million for the quarter, compared to analyst estimates of $29.01 million. During the same quarter in the previous year, the company posted ($1.38) earnings per share. As a group, sell-side analysts forecast that Arrowhead Pharmaceuticals, Inc. will post -2.42 earnings per share for the current fiscal year.

Arrowhead Pharmaceuticals Profile

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.

Want to see what other hedge funds are holding ARWR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.